When did INOZYME PHARMA INC (INZY) report earnings last quarter?
INOZYME PHARMA INC (INZY) last reported earnings on 5/14/2025.
NASDAQ:INZY • US45790W1080
Past quarterly earnings results for INOZYME PHARMA INC (INZY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.44 | -0.42 | -5.86% | -15.79% | - | - | ||
| Q4 2024 | -0.41 | -0.41 | 0.94% | -24.24% | - | - | ||
| Q3 2024 | -0.39 | -0.44 | 12.28% | -34.48% | - | - | ||
| Q2 2024 | -0.44 | -0.40 | -10.77% | -25.71% | - | - | ||
| Q1 2024 | -0.38 | -0.37 | -3.49% | 5.00% | - | - | ||
| Q4 2023 | -0.33 | -0.32 | -1.56% | 21.43% | - | - | ||
| Q3 2023 | -0.29 | -0.32 | 10.11% | 23.68% | - | - | ||
| Q2 2023 | -0.35 | -0.44 | 20.75% | 7.89% | - | - | ||
| Q1 2023 | -0.40 | -0.45 | 12.07% | 43.66% | - | - | ||
| Q4 2022 | -0.42 | -0.46 | 8.84% | 46.84% | - | - | ||
| Q3 2022 | -0.38 | -0.44 | 14.22% | 36.67% | - | - | ||
| Q2 2022 | -0.38 | -0.49 | 22.15% | 28.30% | - | - | ||
| Q1 2022 | -0.71 | -0.84 | 15.28% | -51.06% | - | - | ||
| Q4 2021 | -0.79 | -0.70 | -13.07% | 21.78% | - | - | ||
| Q3 2021 | -0.60 | -0.62 | 3.65% | 61.29% | - | - | ||
| Q2 2021 | -0.53 | -0.58 | 8.84% | 93.00% | - | - | ||
| Q1 2021 | -0.47 | -0.55 | 14.91% | - | - | - | ||
| Q4 2020 | -1.01 | -0.56 | -81.35% | - | - | - | ||
| Q3 2020 | -1.55 | -0.52 | -197.96% | - | - | - | ||
| Q2 2020 | -7.57 | -1.44 | -425.42% | - | - | - | ||
| Q1 2020 | - | - | - | - |
Notes
INOZYME PHARMA INC (INZY) last reported earnings on 5/14/2025.
INOZYME PHARMA INC (INZY) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, INOZYME PHARMA INC (INZY) has beaten EPS estimates in 2 out of 4 releases.